Sarunājas Rita Ruduša un Latvijas Universitātes Filozofijas un socioloģijas institūta vadošais pētnieks Kaspars Zellis.

The system will shut down in 38 minute(s).

Sen, sen atpakaļ telefonā biju ielicis Zoščenko stāstus. Tie ir ļoti īsi, attiecīgi piemēroti lasīšanai, ja kaut ko jāgaida. It kā tie esot smieklīgi, bet humors tajos ir tik īpatnējs, ka smiekli lielākoties nemaz nenāk. Es tos lasu drīzāk kā laikmeta liecību. Stāstu norises laiks un vieta ir PSRS starp abiem Pasaules kariem. Kādu laiku stāstus pat lasīju priekšā bērniem. Meita pieprasīja, kaut arī man šķita, ka tie galīgi nav bērniem piemēroti. Visus mazos stāstiņus vēl neesmu izlasījis, bet gan jau kādreiz. Ieinteresējos par pašu autoru. Mihaila Zoščenko tēvs ir ukrainis, māte krieviete. Dzimis Poltavā, mūsdienu Ukrainā (citur raksta, ka Sanktpēterburgā, Krievijā). Pabeidzis ģimnāziju, bet no universitātes Juridiskās fakultātes izslēgts par nemaksāšanu. Sācies Pirmais pasaules karš, jaunais Zoščenko gribējis mirt un kļuvis par brīvprātīgo. Nesanāca. Vairākas reizes apbalvots. Cietis uzbrukumā ar gāzi, kopš tā laika slimojis ar sirdskaiti un izslēgts no armijas. Trīs gadu laikā Zoščenko izmēģinājis 10 profesijas un mainījis 12 pilsētas. Tad atgriezies armijā, bet pēc sirdslēkmes atkal demobilizēts. Mihails Zoščenko sācis rakstīt īsus, humoristiskus stāstus un kļuvis ārkārtīgi populārs. Iespējams, valstī, kurā grūti saprast, vai vispār par kaut ko var jokot, viņam nebija lielas konkurences. Tomēr kā cilvēks Zoščenko nebija nekāds prieka iemiesojums. Mūsdienās viņam diagnosticētu smagu depresiju, ja ne vēl ko nopietnāku. Autors centies ārstēties, apmeklējis dakterus, centies no sirds, bet kādā brīdī palicis tik slikti, ka pat piecelties no grīdas un paēst nav spējis. “Pirms saullēkta” ir autora mūža darbs. Viņš tajā meklējis un arī atradis veidu, kā izkļūt no depresijas. Tā ir ļoti atklāta, bet ne naturāla grāmata. Kad vajadzēja evakuēties no Maskavas, bija atļauts ņemt līdzi 12 kilogramus bagāžas. Astoņus no tiem aizņēma piezīmes šai grāmatai. PSRS vadītājiem nepatika autora popularitāte. Turklāt autors žurnālā sāka publicēt savu “Pirms saullēkta”. Tika publicētas pirmās sešas nodaļas. Pēc tam tika pavēlēts darbu vairs nedrukāt. Tas esot pārāk nepiemērots padomju lasītājam. Lai izrēķinātos ar autoru, ieganstam paņēma kādu bērnu stāstu par pērtiķīti. Tas tika bargi nokritizēts, rakstnieks izmests no visiem amatiem un savienībām. Iztikas pelnīšanai Zoščenko strādājis pat par kurpnieku. Bet tad nomiris Staļins. Zoščenko atjaunoja rakstnieku savienībā. Tad atbrauca angļu studenti un publiskā pasākumā pajautāja autoram, ko viņš domā par savu izslēgšanu no savienības. Zoščenko atbildējis, ka sevi par vainīgu nav uzskatījis. Par šo brīvdomīgo atbildi Zoščenko no rakstnieku savienības izslēdza atkārtoti. Pēc četriem gadiem autors mira, tā arī neredzējis savu mūža darbu publicētu. Cilvēks karojis par PSRS, bijis pārliecināts komunists, iepriecinājis daudzus līdzcilvēkus visnotaļ drūmajos divdesmitajos un trīsdesmitajos gados, rakstījis humoristiskas lugas pieaugušajiem un stāstus bērniem par Ļeņinu, izsmējis fašismu, atkal devies uz fronti, galu galā uzrakstījis pret sevi diezgan nežēlīgu darbu, lai tikai, iespējams, palīdzētu citiem, un ko viņš ieguva? Praktisku iznīcināšanu, pie tam divas reizes. Jutos ieintriģēts. Kas gan tik briesmīgs viņa grāmatā ir bijis? Sameklēju eksemplāru archive.org angļu valodā un ķēros klāt. Autors stāsta, ka kopš jaunības viņu allaž pavadījušas skumjas, drūmums un melanholija. Iemeslu viņš nav zinājis, bet ticējis, ka pesimistisks skatījums uz dzīvi piedienas tādam domājošam cilvēkam no labi situētas ģimenes kā viņš. Armijā viņš devies brīvprātīgi, jo gribējis mirt. Tomēr karā viņš juties gandrīz vai laimīgs. Pēc kara beigām skumjas atgriezušās. Viņa teoriju, ka nomāktība ir inteliģences pazīme, satriecis kāds sanatorijā sastapts muļķis, kas sirdzis ar līdzīgu kaiti. Autors lasījis grāmatas, izrakstījis citātus, kur cilvēki jutušies līdzīgi viņam. Un tad izspriedis, ka iemesls slēpjas viņa paša dzīves notikumos. Tikai kuros? Tālāk seko autora emocionālākās dzīves epizodes. Ārkārtīgi koncentrēti Zoščenko aprakstījis dažādus notikumus. Piemēram, randiņu vai atgadījumus karā. Katra epizode ir vidēji vienu lappusi īsa. Autors nav centies izstāstīt visu līdz galam, reizēm nav pat pieminējis savas izjūtas, ko tāpat var noprast. Ir situācijas apraksts un notikums. Kā izrādās, ar to pietiek, lai panāktu mulsinoši spēcīgu emocionālu iespaidu. Reti kurai daiļliteratūrai, Zoščenko stāstus ieskaitot, piemīt līdzīgs efekts. Autora talants ir apbrīnojams. Pēc apmēram pusgrāmatas autors stāstiem liek punktu. Viņš apmeklē savas bērnības mājas, pēc kā viņam paliek tikai skumjāk. Tad autors pievēršas savu sapņu jeb drīzāk murgu analīzei. Viņš dodas pie speciālistiem, bet tajā laikā modē ir Freida seksuālās interpretācijas, kas autoram nešķiet pieņemamas. Bet, ņemot talkā Pavlova atklātos nosacījumu refleksus, viņš turpina meklēt pats savas interpretācijas. Autoraprāt, meklējumi ir sekmīgi. Teiksim, viņu sagrābjoša roka un tīģeri sapņos. Divu gadu vecumā viņam izdarīta operācija bez anestēzijas. Mamma aiz operācijas zāles durvīm, dzirdot viņa kliedzienus, noģībusi. No tā laika bezapziņā palikušas bailes no rokām un asmeņiem. Pēc baiļu cēloņu noskaidrošanas Zoščenko jūt, ka bailēm vairs nav tādas varas pār viņu. Autors sevi uzskata par izveseļojušos. Tālāk Zoščenko piemēro sevis atklātos psihes principus dažādiem citiem cilvēkiem viņu situācijās un redz, ka viņam ir taisnība. Autors pat analizē dažādu slavenu krievu rakstnieku dzīves. Viņš piemin arī, ka zinātnieki atklājuši cilvēku izstarotus elektromagnētiskus viļņus, ko latviešu valodā droši vien apzīmētu kā auru. Seko gan epilogs, gan pēcvārds. Tajos autors raksta jau pavisam apcerīgi. Bet tāda arī grāmata ar laiku paliek, pēc saviem koncentrētajiem stāstiem grāmata palēnām kļūst par garu, ne sevišķi labi strukturētu eseju. Un tomēr – autora pārliecībā par sevis atrasto metodi ir kaut kas līdz galam nepārliecinošs. Šķiet, ka viņš mēģina pārliecināt pats sevi. Interesants ir tulkotāja Gerija Kerna pēcpēcvārds. Tajā viņš atklāj, ka Zoščenko līdzcilvēkiem atstājis drūmu iespaidu par sevi. Tulkotājs neslēpj šaubas par “Zoščenko metodi”. Viņš arī pastāsta, ka gadu pēc šīs grāmatas publicēšanas pārtraukšanas Zoščenko esot saticis kādu Čukovski. Tas viņam esot teicis, ka īsās epizodes esot tik vienkāršas un dabiskas, ka autors visdrīzāk pat neapjaušot savu meistarību. Čukovskis ieteicis epizodes izņemt no pārējā teksta un publicēt atsevišķi. Zoščenko apvainots reaģējis – Ko tu saki? Izņemt tās ārā? Ko tu iedomājies, izņemt tās ārā? Pirmajā brīdī gribas Čukovskim piekrist. Ir žēl, ka īsās, spilgtās epizodes pazūd pārējā darba specifikas un kvalitātes trūkuma dēļ. Tomēr grūti pateikt, kā izskatītos īsās epizodes ārpus konteksta. Iespējams, nemaz ne tik labi. Bet vai ir vērts lasīt pilnīgu visu grāmatu? Manuprāt, nē. Var jau būt, ka kādam līdzēs autora interpretācijas un pārdomas, bet lielas cerības es uz to neliktu. Nedomāju, ka grāmata kādreiz sagaidīs savu tulkojumu latviešu valodā, un nevajag arī. Lasīju ilgi, vismaz mēnesi. Sākums aizraujošs, beigas mazliet mokošas. Bet man personīgi šī grāmata kopā ar autora īsajiem stāstiem, viņa paša biogrāfiju un tā laika brutālo vidi veido vienu veselumu. Kopumā tas viss šķiet skumji un muļķīgi. Sava laikmeta liecība. Subjektīvais baudījums 7/10. Visbeidzot ielikšu vienu epizodi savā tulkojumā no angļu valodas. > Pie vecmāmiņas > > Mēs ciemojamies pie vecmāmiņas. Sēžam pie galda. Tiek pasniegtas pusdienas. > > Mūsu vecmāmiņa sēž blakus mūsu vectētiņam. Vectētiņš ir resns un gauss. Viņš izskatās pēc lauvas. Un vecmāmiņa izskatās pēc lauvenes. > > Lauva un lauvene sēž pie galda. > > Es pa laikam pablenžu uz vecmāmiņu. Viņa ir mammas mamma. Viņai ir sirmi mati. Un tumša, pārsteidzoši skaista seja. Mamma teica, ka jaunībā viņa bijusi neparasti skaista. > > Tiek ienesta zupas terīne. > > Tas nav interesanti. Es to tikpat kā neēdu. > > Bet tagad tiek ienesti pīrādziņi. Tas nav slikti. > > Vectētiņš visiem ielej zupu. Pasniedzis viņam savu šķīvi, saku vectētiņam: > > – Man tikai pilīti. > > Vectētiņš tur pavārnīcu pār manu šķīvi. Viena pilīte zupas iekrīt manā šķīvī. > > Pārsteigts un aizkaitināts skatos uz pilīti. > > Visi smejas. > > Vectētiņš saka: > > – Viņš prasīja pilīti. Es izdarīju kā viņš teica. > > Es negribēju zupu, bet nez kāpēc jutos sāpināts. Es gandrīz raudāju. > > Vecmāmiņa teica: > > – Vectētiņš tikai pajokojās. Dod man savu šķīvi, es to piepildīšu. > > Es viņai neiedevu savu šķīvi un pat nepieskāros pīrādziņiem. > > Vectēvs teica mammai: > > – Viņš ir slikts puika. Viņš nesaprot jokus. > > Mamma man teica: > > – Uzsmaidi vectētiņam. Atbildi viņam. > > Es dusmīgi palūkojos uz vectētiņu. Klusi teicu viņam: > > – Es vairs nekad nenākšu tevi apciemot. > > Es gāju ciemos pie vecmāmiņas vienīgi pēc vectētiņa nāves. Viņš nebija mans īstais vectētiņš. Un man nebija žēl, ka viņš nomira. ### Share this: * Share on X (Opens in new window) X * Share on Facebook (Opens in new window) Facebook * More * * Print (Opens in new window) Print * Email a link to a friend (Opens in new window) Email * Share on LinkedIn (Opens in new window) LinkedIn * Share on Reddit (Opens in new window) Reddit * Share on Tumblr (Opens in new window) Tumblr * Share on Pinterest (Opens in new window) Pinterest * Share on Telegram (Opens in new window) Telegram * Share on WhatsApp (Opens in new window) WhatsApp * ### Like this: Like Loading…

The Sheriff’s Office asked the court to authorize an application for the Office of Court Administration (OCA) Public Safety Report System (PSRS) API Integration grant, which reimburses one‑time costs to connect local jail or case management systems to PSRS via APIs; the RFGA and grant terms were attached.

This press release must not be circulated, published or distributed, directly or indirectly, within or to the United States of America, Canada, Australia or Japan. This press release does not constitute an offer and is provided for information purposes only.   * Capital increase with preferential subscription rights (PSRs) maintained successfully completed, raising gross proceeds of €9.7 million, including share premium (total demand of €10.1 million, representing a subscription rate of 104.3%); * Issue of 32,294,779 new shares at a subscription price of €0.30 per share, each new share carrying one warrant; * Renewed support from reference shareholder Nice & Green, which converted approximately €6.0 million of debt through set-off of receivables, resulting in a substantial reduction in financial debt and recurring savings in financing costs over the next three fiscal years; * Settlement-delivery and admission to trading of the New Shares and Warrants on Euronext Growth Paris scheduled for October 29, 2026. The Warrants represent up to €9.7 million in potential additional financing through the end of 2028.   * €17.6 million of equity raised and €9.0 million reduction in gross debt achieved through the two most recent transactions; * Funding requirements secured through September 30, 2027, ahead of the expected contribution from the monetization of the Willa™ cosmetics platform.   Chassieu (France), 27 October 2026 – 8.00 pm – Amoéba (FR0011051598 - ALMIB ), an industrial greentech company specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces the results of its capital increase with preferential subscription rights ("PSRs") maintained, through the issuance of shares with warrants attached (the "ABSAs"), launched on October 2, 2026 (the "Capital Increase"). Following the subscription period, which closed on October 23, 2026, the Capital Increase resulted in the issuance of 32,294,779 new shares (the “New Shares”), each carrying one share subscription warrant (the “Warrants”), at a subscription price of €0.30 per share, representing aggregate gross proceeds of €9,688,433.70, including share premium. Subscriptions were paid up through cash contributions amounting to €3,702,095.40 and through the set-off of €5,986,338.30 of bondholder receivables held by Nice & Green, the Company's reference shareholder.   Including the €7.9 million of gross proceeds raised through the private placement completed with qualified investors in September 2026[1], Amoéba has secured aggregate gross proceeds of €17.6 million (including €7.6 million in cash), demonstrating investors' confidence in the Company's growth trajectory. Nice & Green, Amoéba's reference shareholder, renewed its support for the Company by subscribing approximately €6.0 million to the transaction through the conversion of its bondholder receivable, increasing its ownership interest to 34.1% of the share capital. Combined with the €3.0 million debt conversion already completed as part of the September 2026 private placement, Amoéba's bond debt owed to Nice & Green has been reduced to €3.0 million following the transaction (compared with €11.9 million as of June 30, 2026). The transaction is expected to reduce financing costs by approximately €0.5 million per year, representing total estimated savings of €1.5 million over the next three years. All other terms of the financing remain unchanged, with repayment of the principal amount of the straight bonds still scheduled for September 2029. The funds raised are expected to cover Amoéba's financing requirements through September 30, 2027. Beyond that date, the monetization of its Willa™ cosmetics asset is expected to provide the Company with sufficient financial resources to achieve financial self-sufficiency by 2029. Subject to the successful monetization of this asset, this financing is therefore expected to represent the Company's last recourse to the capital markets until then. For reference, Amoéba is targeting revenue of approximately €40 million with a current operating margin exceeding 10% by that time. Thereafter, based on its business development plan, the Company aims to double its revenue to approximately €80 million by 2032 while nearly doubling its current operating margin as a percentage of revenue.   Jean-François DOUCET, CEO of Amoéba, commented: “The successful completion of these two capital raisings marks a major milestone for Amoéba. I would like to sincerely thank all investors, both existing and new, who placed their trust in us through these two transactions, completed in a particularly demanding market environment, and especially Nice & Green, our reference shareholder, whose continued support also enables us to significantly reduce our debt burden. We now look to the future with confidence and strengthened financial resources. In biocontrol, we are ready to accelerate the execution of our commercial roadmap alongside our leading partners, while expanding the scope of application of our AXPERA technology to additional crops not currently covered by existing agreements. The first significant commercial volumes are expected during the 2027 season. In cosmetics, we are steadily advancing discussions with several major industry players to maximize the value of our asset. The monetization of this asset should allow us to avoid any further recourse to the capital markets until we achieve financial self-sufficiency by 2029. Amoéba is now a revenue-generating company fully focused on unlocking the value of its technologies and assets for the benefit of all its stakeholders.”   Results of the capital increase Subscription demand Total demand amounted to 33,680,048 ABSAs, representing a total subscription amount of €10,104,014.40, corresponding to a 104.29% subscription rate relative to the 32,294,779 ABSAs initially offered. Demand was allocated as follows: * 15,848,541 ABSAs subscribed on an irreducible basis; * 492,101 ABSAs subscribed on a reducible basis; * 17,339,406 ABSAs subscribed on an unrestricted basis. Allocation of the ABSAs Subscriptions submitted on an irreducible and reducible basis were fully allocated. Making use of the authorization provided under Article L.225-134 I-2° of the French Commercial Code, the Chief Executive Officer, acting pursuant to powers sub-delegated by the Board of Directors, reduced the allocation of ABSAs subscribed on an unrestricted basis to 15,954,137 ABSAs. This adjustment enabled the total number of ABSAs issued to be limited to the 32,294,779 ABSAs offered as part of the Capital Increase. Reminder regarding the use of proceeds The net proceeds of the Capital Increase, prior to any potential exercise of the Warrants, will be used to fund the Company's ongoing operations, with approximately 30% allocated to commercial development initiatives and approximately 70% to working capital and general corporate purposes. The €6.0 million portion of the Capital Increase subscribed through the set-off of receivables will result in an equivalent reduction in the Company's debt and generate corresponding savings in financing costs. Based on the proceeds raised, the Company believes it has sufficient financial resources to fund its operations through September 30, 2027. Thereafter, the expected monetization of its cosmetics platform from 2027 onwards is intended to provide the funding required to support the Company until it reaches financial self-sufficiency. Settlement and delivery and admission to trading Settlement and delivery of the 32,294,779 ABSAs will take place on October 29, 2026. The New Shares will carry current dividend rights (jouissance courante) and will be fully fungible with the Company's existing shares immediately upon issuance. They will be admitted to trading on Euronext Growth Paris on October 29, 2026, on the same trading line as the existing shares, under ISIN code FR0011051598 and the ticker ALMIB. The Warrants will be detached from the New Shares upon issuance and admitted to trading on Euronext Growth Paris on October 29, 2026, under ISIN code FR001401BD07. Two Warrants will entitle their holder to subscribe for one new ordinary share of the Company at an exercise price of €0.60 per share until and including December 31, 2028, subject to customary legal and contractual anti-dilution adjustments. Warrants not exercised by that date will automatically lapse and become null and void. The full exercise of all Warrants could result in the issuance of a maximum of 16,147,389 additional new shares, corresponding to a maximum nominal capital increase of €322,947 and maximum gross proceeds of €9,688,433, including share premium. Following settlement and delivery of the transaction, the Company's share capital will amount to €2,583,582.34, divided into 129,179,117 ordinary shares with a par value of €0.02 each.   Next steps October 29, 2026 Settlement and delivery of the transaction and completion of the Capital Increase Admission to trading of the new shares on Euronext Growth Paris Admission to trading of the Warrants on Euronext Growth Paris December 31,2028 End of the Warrant exercise period   Impact of the capital increase Impact on share capital and voting rights To the best of the Company's knowledge, the breakdown of share capital and voting rights prior to the Capital Increase was as follows: Shareholders Number of shares & voting rights % of share capital and voting rights NICE & GREEN 24,126,197 24.90% Free float[2] 72,724,775 75.06% Treasury 33,366 0.03% TOTAL 96,884,338 100.00%   Following settlement and delivery of the Capital Increase and prior to any exercise of the Warrants, the Company's share capital and voting rights will be allocated as follows: Shareholders Number of shares & voting rights % of share capital and voting rights NICE & GREEN 44,080,658 34.12% Free float 85,065,093 65.85% Treasury 33,366 0.03% TOTAL 129,179,117 100.00%   Following the full exercise of all Warrants, the Company's share capital and voting rights would be allocated as follows (assuming that the Warrants are exercised by their initial subscribers): Shareholders Number of shares & voting rights % of share capital and voting rights NICE & GREEN 54,057,888 37.20% Free float 91,235,252 62.78% Treasury 33,366 0.02% TOTAL 145,326,506 100.00 %   Impact on shareholders' equity per share For illustrative purposes, the impact of the issuance of the New Shares and the exercise of the Warrants on shareholders' equity per share (based on the Company's consolidated shareholders' equity as of June 30, 2026, unaudited, adjusted for the proceeds of the private placement completed in September 2026, and the number of shares outstanding as of that date) is as follows:     Undiluted basis Diluted basis** Before the issuance of the new shares resulting from the capital increase 0.0202 0.0199 After the issuance of 32,294,779 new shares resulting from the capital increase 0.0902 0.0892 After the issuance of 32,294,779 new shares pursuant to the Capital Increase and 16,147,389 additional new shares following the full exercise of the Warrants 0.1468 0.1455 * Based on consolidated shareholders' equity of €1.96 million as of June 30, 2026, including the funds raised through the private placement completed in September 2026, and assuming the transaction is carried out before transaction costs. ** There are currently 1,339,000 free shares outstanding.   Impact on shareholders' interests For illustrative purposes, the impact of the Capital Increase on the shareholding interest of a shareholder holding 1% of the Company's share capital prior to the transaction and not participating in the Capital Increase (calculations based on the number of shares comprising the Company's share capital as of the launch date of the transaction) would be as follows: Shareholder's interest (%)   Undiluted basis Diluted basis** Before the issuance of the New Shares resulting from the capital increase 1,00% 0,99% After the issuance of 32,294,779 new shares resulting from the capital increase 0,75% 0,74% After the issuance of 32,294,779 new shares pursuant to the Capital Increase and 16,147,389 additional new shares following the full exercise of the Warrants 0,67% 0,66% ** : There are currently 1,339,000 free shares outstanding.     Legal framework of the transaction The Capital Increase was decided on September 30, 2026 by the Company's Board of Directors, acting pursuant to the authority delegated to it by the Combined General Meeting of Shareholders held on April 3, 2026 under its 13th resolution, in accordance with Articles L.225-129-2, L.225-132 and L.228-91 et seq. of the French Commercial Code. The completion of the Capital Increase will be recorded on October 29, 2026, on the basis of the custodian's certificate issued by UPTEVIA, acting as centralizing agent, and, with respect to subscriptions paid through the set-off of receivables, on the basis of the statutory auditors' certificate serving in lieu of the custodian's certificate in accordance with Article L.225-146 of the French Commercial Code.   Public information Pursuant to Article 1er, paragraph 4, subparagraph (d bis) of Regulation (EU) 2017/1129 of the European Parliament and of the Council dated June 14, 2017, as amended (the "Prospectus Regulation"), the offering did not require the preparation of a prospectus subject to the approval of the French Financial Markets Authority (the "AMF"). An information document prepared in accordance with Annex IX of the Prospectus Regulation was filed with the AMF and published on October 2, 2026. This document has neither been reviewed nor approved by the AMF. It is available free of charge on the Company's website at: https://amoeba-nature.com/investisseur/information-financiere/. A notice to shareholders relating to the Capital Increase was published in the French Bulletin of Mandatory Legal Notices (BALO) on October 2, 2026. The results of the Capital Increase are the subject of a Euronext notice published today.   Risk factors Risk Factors Relating to the Issuer Investors are invited to carefully consider the risk factors relating to the Company and its business described in the 2025 Universal Registration Document filed with the AMF on March 18, 2026 under number D.26-0108, and in the information document prepared in accordance with Annex IX of the Prospectus Regulation and published on October 2, 2026, both of which are available free of charge on the Company's website at: https://amoeba-nature.com/investisseur/information-financiere/. Risk Factors Relating to the Securities Issued In addition to the risk factors specific to the Issuer, shareholders and holders of Warrants are invited to consider the following risk factors relating to the securities being issued: * The market price of the Company's shares may fluctuate and could fall below the subscription price of shares issued upon exercise of preferential subscription rights; * Sales of the Company's shares or preferential subscription rights could adversely affect the market price of the shares or of the preferential subscription rights; * The Warrants will only have intrinsic value if the Company's share price exceeds their exercise price of €0.60 per share; they will expire automatically if not exercised by December 31, 2028; liquidity in the market for the Warrants cannot be guaranteed; and the exercise of the Warrants will result in additional dilution for shareholders who do not hold them.   Transaction Advisors EuroLand Corporate - Transaction advisor  Marex - Lead manager and Bookrunner  Lamy Lexel - Legal counsel ACTUS finance & communication - Financial communication    About Amoéba : Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the management of microbiological risk through the patented use of amoebae in the plant protection and cosmetics sectors. With expertise that is unique in the world and protected by numerous patents, Amoéba is currently the only company authorised to utilise the Willaertia amoeba on an industrial scale for biocontrol and cosmetic applications. To the Company's knowledge, it is also the only firm capable of producing this amoeba on an industrial scale in volumes suitable for commercial applications, thereby offering a viable alternative to the chemical products widely used today. Amoéba is currently focusing on the global biocontrol market for plant protection and the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory authorisations, the Company has undertaken the necessary regulatory procedures and submitted registration applications in Europe and the United States. As regards the active substance, it had already obtained approval in the US in 2022 and a positive, final opinion from EFSA in Europe. Registration of the AXPERA product was granted in 2025 for the United States and in 2026 in France, followed by other targeted European countries. As for the cosmetic application, this does not require prior approval from a competent authority in Europe or the United States. The cosmetic ingredient is already listed on the INCI (International Nomenclature of Cosmetic Ingredients) list, paving the way for its global marketing, except in China where local approval is required. Amoéba is a company listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme. Further information is available at www.amoeba-nature.com   Contacts: ACTUS Finance & Communication Droit Devant Investor Relations Pierre JACQUEMIN-GUILLAUME 01 53 67 36 79 amoeba@actus.fr Financial Press Relations Serena BONI 04 72 18 04 92 sboni@actus.fr Trade and general public press relations Laëtitia PINTO 07 64 83 39 85 pinto@droitdevant.fr   Disclaimers This press release contains ‘forward-looking statements'. All statements other than statements of historical fact included in this press release, including, without limitation, those concerning the Company's financial position, business strategy, plans and management's objectives for future operations, are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance or achievements, or the results of the industry, to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding the Company's current and future business strategies and the environment in which the Company will operate in the future. Other factors could lead to significant differences in actual results, performance or achievements. The Company expressly disclaims any obligation or undertaking to update or amend the forward-looking statements contained in this press release, whether as a result of new information, future developments or for any other reason. This press release and the information contained therein do not constitute an offer to sell or a solicitation of an offer to buy, or a solicitation to sell or buy, any securities, and no sale of securities will take place in any state or jurisdiction where such an offer, solicitation or sale would be unlawful without registration or approval under the securities laws of that state or jurisdiction. This press release does not constitute an offer to sell securities or a solicitation of an offer to purchase securities in the United States or in any other jurisdiction. The securities referred to in this press release may not be offered or sold in the United States without registration or an exemption from registration under the US Securities Act of 1933, as amended. The Company does not intend to register the offer, in whole or in part, in the United States, nor does it intend to make a public offering in the United States. This press release does not contain, nor does it constitute, an invitation, an encouragement or an inducement to invest. This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the ‘Prospectus Regulation'). With regard to the Member States of the European Economic Area (other than France) (the ‘Relevant States'), no action has been taken and will not be taken to enable a public offer of securities that would require the publication of a prospectus in any Relevant State. Consequently, the securities may not be, and will not be, offered in any of the Relevant States, except in accordance with the exemptions provided for in Article 1 (4) of the Prospectus Regulation or in other cases where the Company is not required to publish a prospectus pursuant to Article 3(2) of the Prospectus Regulation and/or the applicable regulations in those Relevant States. This press release is intended solely for persons (i) who are not in the United Kingdom, subject to applicable regulations; (ii) who are ‘investment professionals' meeting the requirements of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the ‘Order'); (iii) who are persons falling within the provisions of Article 49(2)(a) to (d) (‘high net worth companies, unincorporated associations, etc.') of the Order; or (iv) any other person to whom this press release may be addressed in accordance with the law (the persons referred to in paragraphs (i) to (iv) being collectively referred to as ‘Eligible Persons'). Any investment or investment activity relating to this press release is restricted to Qualified Persons and may only be undertaken by such persons. Any person other than a Qualified Person must refrain from using or relying on this press release and the information contained therein. With regard to the United Kingdom, securities may not be offered or sold without the publication of a prospectus in the United Kingdom or an exemption from such publication under Regulation (EU) 2017/1129 as amended, in so far as it forms part of UK domestic law pursuant to the European Union (Withdrawal) Act 2018 (Withdrawal) (‘UK Prospectus Regulation'). Consequently, this press release is directed solely at persons who are ‘qualified investors' within the meaning of Article 2(e) of the UK Prospectus Regulation. The publication, distribution or dissemination of this press release in certain countries may constitute a breach of applicable laws and regulations. Consequently, persons physically present in those countries in which this press release is disseminated, published or distributed must inform themselves of and comply with such laws and regulations. This press release must not be distributed, disseminated or published, directly or indirectly, in the United States, Canada, Japan or Australia.   --- [1] See the press release dated September 25, 2026. [2] Including Koppert. ------------------------ This publication embed "🔒 Actusnews SECURITY MASTER". - SECURITY MASTER Key: yGtplcdoaJedx2uaY5tuZ2dmbpiVlpOUbGTJlWial5rIaJ+SmWaTZ8mSamlilWdn - Check this key: https://www.security-master-key.com. ------------------------Communiqué intégral et original au format PDF : Télécharger le PDF © Copyright Actusnews Wire Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com ---